Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.790
-0.200 (-5.01%)
Jan 30, 2026, 4:00 PM EST - Market closed
Cellectis Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 75.27 | 41.51 | 0.76 | 19.17 | 30.35 | 51.06 |
Other Revenue | 7.28 | 7.71 | 8.44 | 6.55 | 8.25 | 8.51 |
| 82.55 | 49.22 | 9.19 | 25.72 | 38.6 | 59.56 | |
Revenue Growth (YoY) | 129.04% | 435.38% | -64.26% | -33.35% | -35.20% | 159.09% |
Cost of Revenue | - | - | 0.74 | 1.77 | 1.84 | 1.95 |
Gross Profit | 82.55 | 49.22 | 8.46 | 23.95 | 36.75 | 57.61 |
Selling, General & Admin | 19.92 | 19.09 | 16.81 | 17.49 | 22.88 | 22.51 |
Research & Development | 89.95 | 90.54 | 87.65 | 97.5 | 117.84 | 77.05 |
Other Operating Expenses | -0.91 | -0.85 | 0.8 | -1.38 | -0.49 | 0.36 |
Operating Expenses | 108.96 | 108.77 | 105.26 | 113.62 | 140.23 | 99.92 |
Operating Income | -26.41 | -59.56 | -96.8 | -89.67 | -103.48 | -42.31 |
Interest Expense | -7.98 | -7.45 | -5.31 | -3.79 | -4.17 | -2.41 |
Interest & Investment Income | 10.99 | 11.28 | 3.61 | 1.12 | 0.72 | 1.39 |
Currency Exchange Gain (Loss) | -7.38 | 7.33 | 4.22 | 6.06 | 9.74 | -10.59 |
Other Non Operating Income (Expenses) | -1.41 | 0 | -1.12 | -12.33 | 0.44 | 0.34 |
EBT Excluding Unusual Items | -32.18 | -48.4 | -95.4 | -98.6 | -96.75 | -53.58 |
Gain (Loss) on Sale of Investments | -2.66 | 11.64 | -20.57 | - | - | - |
Legal Settlements | - | - | -0.5 | - | - | - |
Pretax Income | -34.84 | -36.76 | -116.46 | -98.6 | -96.75 | -53.58 |
Income Tax Expense | 0.51 | - | 0.37 | 0.09 | - | - |
Earnings From Continuing Operations | -35.35 | -36.76 | -116.84 | -98.69 | -96.75 | -53.58 |
Earnings From Discontinued Operations | - | - | 8.39 | -15.35 | -28.36 | -43.9 |
Net Income to Company | -35.35 | -36.76 | -108.44 | -114.03 | -125.11 | -97.48 |
Minority Interest in Earnings | - | - | 7.38 | 7.89 | 10.91 | 16.41 |
Net Income | -35.35 | -36.76 | -101.06 | -106.14 | -114.2 | -81.07 |
Net Income to Common | -35.35 | -36.76 | -101.06 | -106.14 | -114.2 | -81.07 |
Shares Outstanding (Basic) | 100 | 91 | 57 | 46 | 45 | 43 |
Shares Outstanding (Diluted) | 100 | 91 | 57 | 46 | 45 | 43 |
Shares Change (YoY) | 22.47% | 58.85% | 25.17% | 1.62% | 5.45% | 0.14% |
EPS (Basic) | -0.35 | -0.41 | -1.77 | -2.33 | -2.55 | -1.91 |
EPS (Diluted) | -0.35 | -0.41 | -1.77 | -2.33 | -2.55 | -1.91 |
Free Cash Flow | -31.52 | 20.41 | -25.82 | -89.88 | -123.11 | -124.34 |
Free Cash Flow Per Share | -0.31 | 0.23 | -0.45 | -1.97 | -2.75 | -2.92 |
Gross Margin | 100.00% | 100.00% | 91.98% | 93.11% | 95.22% | 96.73% |
Operating Margin | -31.99% | -121.01% | -1053.00% | -348.57% | -268.11% | -71.03% |
Profit Margin | -42.83% | -74.69% | -1099.30% | -412.61% | -295.87% | -136.11% |
Free Cash Flow Margin | -38.18% | 41.46% | -280.85% | -349.38% | -318.95% | -208.75% |
EBITDA | -13.87 | -48.25 | -86.75 | -79.77 | -98.65 | -34.68 |
EBITDA Margin | -16.81% | -98.04% | - | - | -255.59% | -58.23% |
D&A For EBITDA | 12.53 | 11.3 | 10.06 | 9.9 | 4.83 | 7.63 |
EBIT | -26.41 | -59.56 | -96.8 | -89.67 | -103.48 | -42.31 |
EBIT Margin | -31.99% | -121.01% | - | - | -268.11% | -71.03% |
Revenue as Reported | 82.55 | 49.22 | 9.19 | 25.73 | 38.6 | 59.56 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.